153 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
Policy in effect from time to time (see Exhibit B attached hereto), and must be submitted to the Company for reimbursement within thirty (30) calendar … the Company’s receipt of the invoice or expense reimbursement request with appropriate documentation.
5. Expenses and Liabilities. (i) Company
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
8 Mar 24
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8:21am
during calendar year 2022 was derived from the Viatris License Agreement signed in the fourth quarter, and to a lesser extent, from the reimbursement
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
Lincoln Park $40,000 as full and complete reimbursement of its expenses in connection with the offering. The remaining shares of our common stock … and a cash fee of $40,000 to Lincoln Park as Lincoln Park's full and complete expense reimbursement in connection with entering into the transaction
8-K
EX-10.1
13iy68vlt2m2 oz72fno
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
8-K
EX-10.1
azw420k7icujrs
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
8-K
EX-99.1
361ny1i
13 Nov 23
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
8:12am
8-K
EX-10.1
je3jev3cy
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
424B5
g4d8tqvgl1eyxc jg
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
caemorul8pe73
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-99.1
63thx2g2mj6
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-99.1
pbqfx6p1yvx
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-10.1
4qmr5o mhoz
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm